Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard Scheiner

Showing results (151-160 of 203) with videos related to

Pageof 21
Sort By:
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2019
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohortBernhard Scheiner, Martha M Kirstein, Florian Hucke, et al.
Hepatology (Baltimore, Md.)|May 21, 2022
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver diseaseLukas Hartl, Katharina Haslinger, Martin Angerer, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2026
Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular riskConstanze Hoebinger, Georg Semmler, Oleksandr Petrenko, et al.
Hepatology (Baltimore, Md.)|July 14, 2020
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver DiseaseGeorg Semmler, Teresa Binter, Karin Kozbial, et al.
Liver Cancer|August 20, 2021
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life CohortFabian Finkelmeier, Bernhard Scheiner, Catherine Leyh, et al.
Cancers|December 11, 2022
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter ExperienceFriedrich Sinner, Matthias Pinter, Bernhard Scheiner, et al.
Oncology Letters|August 27, 2025
Radiomics-based prediction of HCC response to atezolizumab/bevacizumabIsaac Rodriguez, Abhinay Vellala, Timo Itzel, et al.
JHEP Reports : Innovation in Hepatology|May 27, 2024
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic eventsNajib Ben Khaled, Marie Möller, Leonie S Jochheim, et al.
Frontiers in Oncology|March 3, 2023
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitorsY Linda Wu, Grace van Hyfte, Umut Özbek, et al.
Pageof 21

Showing results (151-160 of 203) with videos related to

Sort By:
Pageof 21
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Alimentary Pharmacology & Therapeutics|April 14, 2019
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohortBernhard Scheiner, Martha M Kirstein, Florian Hucke, et al.
Hepatology (Baltimore, Md.)|May 21, 2022
Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver diseaseLukas Hartl, Katharina Haslinger, Martin Angerer, et al.
JHEP Reports : Innovation in Hepatology|June 19, 2026
Alcohol intake reprograms hepatic immune-metabolic circuits to exacerbate murine atherosclerosis and human cardiovascular riskConstanze Hoebinger, Georg Semmler, Oleksandr Petrenko, et al.
Hepatology (Baltimore, Md.)|July 14, 2020
Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver DiseaseGeorg Semmler, Teresa Binter, Karin Kozbial, et al.
Liver Cancer|August 20, 2021
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life CohortFabian Finkelmeier, Bernhard Scheiner, Catherine Leyh, et al.
Cancers|December 11, 2022
Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter ExperienceFriedrich Sinner, Matthias Pinter, Bernhard Scheiner, et al.
Oncology Letters|August 27, 2025
Radiomics-based prediction of HCC response to atezolizumab/bevacizumabIsaac Rodriguez, Abhinay Vellala, Timo Itzel, et al.
JHEP Reports : Innovation in Hepatology|May 27, 2024
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic eventsNajib Ben Khaled, Marie Möller, Leonie S Jochheim, et al.
Frontiers in Oncology|March 3, 2023
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitorsY Linda Wu, Grace van Hyfte, Umut Özbek, et al.
Pageof 21